DENVER — Patients with diabetic macular edema were able to maintain visual acuity improvements long term despite receiving fewer anti-VEGF injections as treatment progressed, according to a study.
At the Association for Research in Vision and Ophthalmology meeting, Blanche L. Kuo told Healio/OSN that previous studies have shown that real-world patients receive fewer anti-VEGF injections than participants in clinical trials.
“We wanted to look at a large data set... to look at what the real-world trends in diabetic macular edema are,” she said.
Using data from the IRIS Registry,